Syros Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Syros Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Syros Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.8M, a 35.9% decline year-over-year.
  • Syros Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $8.88M, a 21.5% decline year-over-year.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10.4M, a 8.55% decline from 2022.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.4M, a 10.2% increase from 2021.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $10.4M, a 5.35% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $10.4M -$976K -8.55% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-27
2022 $11.4M +$1.06M +10.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-27
2021 $10.4M -$585K -5.35% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-02
2020 $10.9M +$1.1M +11.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 $9.84M +$3.23M +48.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-15
2018 $6.61M +$2.19M +49.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 $4.42M +$185K +4.37% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-05
2016 $4.23M +$1M +31% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
2015 $3.23M +$2.3M +245% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2014 $937K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.